IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma

Multiple Myeloma (MM) is a plasma cell neoplasm originating in the bone marrow and is the second most common blood cancer in the United States. One challenge in understanding the pathogenesis of MM and improving treatment is a lack of immunocompetent mouse models. We previously developed the IL6Myc...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	Michael D. Pisano, Fumou Sun, Yan Cheng, Deepak Parashar, Vivian Zhou, Xuefang Jing, Ramakrishna Sompallae, Jenica Abrudan, Michael T. Zimmermann, Angela Mathison, Siegfried Janz, Miles A. Pufall
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2023-07-01
Online Access:	https://haematologica.org/article/view/11148

Similar Items

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma
by: Fumou Sun, et al.
Published: (2020-03-01)

Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma
by: Vivian Zhou, et al.
Published: (2024-07-01)

Interplay: The Essential Role between INSM1 and N-Myc in Aggressive Neuroblastoma
by: Chiachen Chen, et al.
Published: (2022-09-01)

Molecular and immunological determinants of long-term survival in multiple myeloma
by: Khanmi Kasomva, et al.
Published: (2025-10-01)

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway
by: Zhi Wen, et al.
Published: (2025-10-01)

MYC alterations in multiple myeloma: Genetic insights and prognostic impact
by: Sara Cristóbal-Vargas, et al.
Published: (2025-08-01)

Myc rearrangement redefines the stratification of high‐risk multiple myeloma
by: Xianghong Jin, et al.
Published: (2024-06-01)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
by: A. Ortuzar Pasalodos, et al.
Published: (2022-06-01)

Aggressive Multiple Myeloma with Unusual Morphology
by: Mehmet Sönmez, et al.
Published: (2014-12-01)

Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
by: Jung Yoon, et al.
Published: (2024-09-01)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
by: L. Hasan Bou Issa, et al.
Published: (2022-06-01)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
by: Daniele Caracciolo, et al.
Published: (2020-02-01)

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC
by: Stacy Grieve, et al.
Published: (2019-11-01)

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
by: Matthew K. Adams, et al.
Published: (2019-01-01)

FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
by: José Ursic-Bedoya, et al.
Published: (2024-01-01)

MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma
by: Lama Hasan Bou Issa, et al.
Published: (2024-04-01)

Differential Pain‐Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma
by: Marta Diaz‐delCastillo, et al.
Published: (2020-02-01)

ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
by: Oliver J. Mainwaring, et al.
Published: (2023-03-01)

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
by: Laura Chiecchio, et al.
Published: (2009-07-01)

Uncommon radiological findings of aggressive primary central nervous system lymphoma in an immunocompetent patient
by: Sevda Diker, et al.
Published: (2025-02-01)

Myc-Interacting Zinc Finger Protein 1 (Miz-1) Is Essential to Maintain Homeostasis and Immunocompetence of the B Cell Lineage
by: Eva-Maria Piskor, et al.
Published: (2022-03-01)

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
by: Zinab O. Doha, et al.
Published: (2023-09-01)

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma
by: Tianyi Ye, et al.
Published: (2024-05-01)

Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma
by: Yanwei Luo, et al.
Published: (2020-11-01)

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
by: Arianna Giacomini, et al.
Published: (2024-11-01)

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
by: Judith Lind, et al.
Published: (2024-08-01)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
by: Lorraine Davis, et al.
Published: (2022-04-01)

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
by: Jian-rong Li, et al.
Published: (2024-03-01)

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients
by: Maria R. Ambrosio, et al.
Published: (2019-01-01)

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability
by: Zaili Luo, et al.
Published: (2023-02-01)

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
by: Aneta Mikulasova, et al.
Published: (2020-04-01)

Assessment of CD38brightHLA-DR+ T cells using a rapid flow cytometry-based assay to aid in the diagnosis of hemophagocytic lymphohistiocytosis and immune regulatory disorders in adult subjects
by: Aaruni Khanolkar, et al.
Published: (2025-12-01)

Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma
by: Shihao Li, et al.
Published: (2024-04-01)

The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
by: Francesco Maura, et al.
Published: (2024-05-01)

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
by: Laurens E. Franssen, et al.
Published: (2018-08-01)

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma
by: Jessica Bordini, et al.
Published: (2015-06-01)

Aggressive FLC Escape in a Patient with IgD Myeloma
by: Cédric Farges, et al.
Published: (2015-01-01)

A gene signature can predict risk of MGUS progressing to multiple myeloma
by: Fumou Sun, et al.
Published: (2023-06-01)

Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
by: Scott Van Wier, et al.
Published: (2013-10-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)